原題
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: J Clin Oncol (CiteScore 2022: 39.6)
DOI: 10.1200/JCO-25-02957
PMID: 42166704